February 20, 2025 CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial San Carlos, CA – February 20, 2025 – CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject…
Oct 24, 2023 https://www.curasen.com/wp-content/uploads/2023/10/Poster-034-Harrison-CTAD-2023-FINAL2.pdf
October 31, 2023 PDF Version BOSTON–(BUSINESS WIRE)–Oct. 31, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from the Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate,…
Aura Biosciences to Participate in Upcoming Investor ConferencesFebruary 26, 2024PDF Version BOSTON–(BUSINESS WIRE)–Feb. 26, 2024– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: 44th Annual TD…
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at…
February 9, 2023 PDF Version BOSTON–(BUSINESS WIRE)–Feb. 9, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: Live webcasts of the SVB fireside chat and…
